Unresectable Hepatocellular Carcinoma: Imfinzi Plus Imjudo Combination Therapy
Medical Supporter — Informationshinweis
Dieser Artikel ist eine Zusammenfassung internationaler medizinischer Informationen und stellt keine medizinische Beratung dar; er ersetzt nicht die Diagnose oder den Behandlungsplan Ihres behandelnden Arztes. Die dargestellten Informationen stammen aus öffentlichen Veröffentlichungen und offiziellen Angaben führender japanischer medizinischer Einrichtungen; Eignung und Wirkung einer Therapie sind individuell und müssen von einem qualifizierten Arzt beurteilt werden.
FDA Approval of Dual Immunotherapy
On October 24, 2022, AstraZeneca announced the regulatory approval of Imfinzi (durvalumab, anti-PD-L1 antibody) in combination with Imjudo (tremelimumab, anti-CTLA-4 antibody) for the treatment of unresectable hepatocellular carcinoma (HCC) in the United States.
Clinical Context and Unmet Medical Need
Hepatocellular carcinoma represents the most prevalent histological type of liver cancer, accounting for approximately 75% of primary liver malignancies. At diagnosis, approximately 50% of HCC patients present with advanced-stage disease. Among these patients, 80-90% exhibit concurrent hepatic cirrhosis as a comorbid condition. The therapeutic landscape for HCC has historically been limited, with immunotherapy options remaining restricted in scope and efficacy.
HIMALAYA Phase III Clinical Trial Results
The approval was substantiated by data from the HIMALAYA Phase III randomized controlled trial, which enrolled 1,324 treatment-naïve patients with unresectable HCC who were ineligible for locoregional therapy. Patients were randomized into three treatment arms:
- Imfinzi monotherapy (1,500 mg)
- Imfinzi (1,500 mg) plus Imjudo (300 mg) administered every four weeks
- Sorafenib control arm
Key Efficacy and Safety Outcomes
The HIMALAYA trial demonstrated significant clinical benefit with the combination regimen:
Mortality Reduction: The Imfinzi plus Imjudo arm demonstrated a 22% reduction in death risk compared to sorafenib control.
Overall Survival: The estimated 3-year overall survival rates were:
- Imfinzi plus Imjudo: 30%
- Sorafenib: 20%
Clinical Significance
According to Dave Fredrickson, AstraZeneca executive, the approval of Imjudo expands therapeutic options for patients with unresectable HCC in the United States by providing access to CTLA-4 inhibition. This dual-checkpoint immunotherapy approach enhances anti-tumor immune response through complementary mechanisms targeting both PD-L1 and CTLA-4 pathways.
Data Source
Information adapted from: https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-and-imjudo-approved-in-advanced-liver-cancer.html
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Behandlung in Japan im Blick? Brauchen Sie Informationen und Unterstützung?
Wir helfen Ihnen, die für eine medizinische Reise nach Japan nötigen Informationen zu ordnen, kontaktieren japanische Einrichtungen und organisieren eine Zweitmeinungsberatung.Die Erstberatung ist kostenlos; ein Berater hilft Ihnen, die nächsten Schritte zu klären.
Figure 1
Figure 2
Figure 3
Figure 4